Anthropic has purchased the stealth biotech AI startup Coefficient Bio in a $400 million stock deal, according to The Information and Eric Newcomer. Sources close to the deal confirmed to TechCrunch ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The St. Louis Business Journal ...

Jake Fillery is an Evergreen Editor for GameRant who has been writing lists, guides, and reviews since 2022. With thousands of engaging articles and guides, Jake loves conversations surrounding all ...

There are hundreds of biotechnology companies today that have never commercialized a drug. For many years, the standard approach in the industry has been to advance the science, prove the asset, and ...

Allison covers what hot startups are getting up to, and who’s financing them. She is also co-host of the weekly biotech podcast, “The Readout Loud.” You can reach Allison on Signal at AllisonDeAngelis ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Research Scientist in Lab For years, public debate around U.S. dependence on China has ...

The health-care corner of the US equity market has traditionally been viewed as defensive, thanks to steady growth and healthy dividend yields among the industry’s stalwarts. That narrative is ...

For the third year in a row, Fierce Biotech’s Layoff Tracker is topping the tree as the story with the highest number of reads. The relentless nature of industry layoffs has garnered the most ...

Healthcare and biotech stocks have had a rough run since the giddy heights of the Covid pandemic. But now could be the perfect time to consider investing in these beaten-down but high-growth sectors.

If you look at a stock chart mapping the performance of the State Street SPDR S&P Biotech exchange-traded fund since early 2021, it seems to tell a simple story: The biotech sector has been a disaster ...